The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 24th May, 2024, recommended Dividend at 250% i.e. INR 2.5/- per share (face value of INR 1/- each) on the Equity Share Capital of the Company for the financial year 2023-24 subject to the approval of the Shareholders at the up coming Annual General Meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,226 INR | +1.08% | -1.32% | +43.61% |
06-12 | India Equities Close Higher Ahead of US Inflation Data | MT |
06-12 | Glenmark Pharmaceuticals Gets US FDA Final Nod for Esomeprazole Magnesium Capsules | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.61% | 4.1B | |
+20.78% | 43.29B | |
+27.64% | 22.38B | |
+19.11% | 15.51B | |
+18.68% | 14.52B | |
+54.64% | 12.93B | |
-0.05% | 6.79B | |
-11.39% | 6.56B | |
+17.73% | 5.87B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- GLENMARK Stock
- News Glenmark Pharmaceuticals Limited
- Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24